Seattle Genetics Advancing Breakthroughs in Treating Complex Conditions
Seattle Genetics is an established biotechnology company that develops empowered anti-body therapies that are ideal for treating cancer. Seattle Genetics has been leading the industry in making antibody-drug conjugates (ADCs), a special technology that works by harnessing the targeting ability of antibodies so as to deliver cell-killing agents to the cancerous cells. Seattle Genetics is also advancing product pipeline to cover more areas and to come up with unique technology that can revolutionize the pharmaceutical industry.
Seattle Genetics is led by Clay B, Siegall, PhD., the CEO of the company and board chairman. The company has been conducting tests in therapeutic areas like acute myeloid leukemia and Hodgkin lymphoma, all in a bid to come up with solutions to the complex problems that surround the health industry.
Seattle Genetics embracing SEA technology
The sugar-engineered antibody (SEA) technology seeks to help increase the potency of monoclonal antibodies and this is a complementary undertaking that has been embraced by the company. SEA technology offers non-fucosylated antibodies, thereby leading to advanced immune response. One of the key features that have stood out is the fact the SEA technology does not demand genetic modifications to the antibody-producing cells since it is possible to use standard cell conditions.
Trial information for patients
Seattle Genetics clinical trials are studies where the company involves people. The studies facilitate tests to reveal new prevention and diagnostic procedures for several diseases. The trials offer new solutions on treating and preventing diseases and these results may suggest creation of new drugs and combinations that can work best with different patients. Note that these trials are conducted with total regard to safety. All the medical procedures used are tested before approval for application.
Clay B. Siegall, Ph.D
Clay B. Siegall is the Chief Executive Officer of Seattle Genetics and is also a board member in the same company. He co-founded Seattle Genetics in 1998 and has worked with different health institutes before launching Seattle Genetics.